Trials / Completed
CompletedNCT02859246
Mucinex® for Treatment of Filamentary Keratitis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Massachusetts Eye and Ear Infirmary · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.
Detailed description
The study is aimed to determine if oral administration of Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis. Subjects will be instructed to take 600 mg tablets of extended release Mucinex® twice a day (total dose is 1.2 g/day) for 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mucinex® | Mucinex® |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2018-07-01
- Completion
- 2018-07-01
- First posted
- 2016-08-09
- Last updated
- 2020-02-19
- Results posted
- 2020-02-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02859246. Inclusion in this directory is not an endorsement.